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Intensive careAbstract Background: Mortality prediction models are useful in pediatric intensive care units
(PICUs) as risk assessment tools and as a benchmark for the quality of care.
Objectives: To assess the performance of the Pediatric Index of Mortality 2 (PIM2) in terms of cal-
ibration and discrimination between survivors and non-survivors among pediatric patients.
Methods: This is a cohort prospective study including 317 pediatric patients admitted to two PICU
settings in a tertiary care hospital in Egypt over a period of one year (from June 2012 till June 2013).
Collected data included personal characteristics, hospital data, diagnosis, outcome and variables
included in PIM2 scoring.
Results: Non-survivors constituted 8.5%. Most common diagnosis was respiratory diseases
(47.9%). Only CNS morbidities (11.7% of survivors versus 37% of non-survivors, P= 0.001)
and a higher PIM2 score (2.39 ± 5.49 in survivors versus 41.38 ± 36.06 in non-survivors,
P= 0.001) were associated with increased risk of non-survival. The area under the curve (AUC)
for PIM2 is 0.796 (95% CI 0.675–0.916), P< 0.001. The Hosmer–Lemeshow goodness-of-ﬁt was
2.850, 8 df, P= 0.943. PIM2.
Conclusion: The calibration and the discriminative ability of PIM2 scoring system aiming to distin-
guish survivors from non-survivors are satisfactory for this sample of pediatric patients. PIM2 is
easily calculated and is freely available. Thus, this tool provides a good incentive for ICU settings
in Egypt for admission of high risk patients in the light of the limited PICU bed complement capac-
ity in relation to the demands.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).Introduction
Mortality rate of patients admitted to Pediatric Intensive Care
Units (PICUs) is a widely recognized outcome indicator and
was reported to vary from 3.8% to 13% worldwide.1 Several
66 M. Rene labib Youssef et al.scoring models that predict the risk of mortality of pediatric
patients admitted to the intensive care are available.2,3 Mortal-
ity prediction models are useful in PICU settings as risk assess-
ment tools and as a benchmark for the quality of care between
facilities.4 Prediction tools must discriminate well between sur-
vivors and non-survivors and be well calibrated before they
can be applied usefully to assess or standardize comparisons
of PICUs or to correct for case-mix differences between groups
in observational studies.5
Pediatric Index of Mortality (PIM) was ﬁrst developed in
19976 and as most other prognostic scoring systems, was
upgraded to PIM2, which was observed to have better predict-
ability of the outcome of pediatric patients admitted to inten-
sive care.7 PIM2 score is usually applied at the time of
admission to intensive care, unlike other prognostic scores
which can be calculated at time intervals throughout the
patient’s stay in intensive care.7 Several studies have docu-
mented PIM2 as a suitable risk assessment tool for prediction
of mortality among pediatric patients, being the most accurate
among several models, and having the best ﬁt in different diag-
nostic and risk groups.8 It is recent, freely available while many
other rating tools need a license and in addition, PIM2 has a
small number of variables, thus it is easily calculated.4,9 We
aimed in the current study to assess the performance of
PIM2, in terms of discriminatory ability and calibration in a
sample of Egyptian children admitted to the PICU.
Materials and methods
Study design and study settings
This is a prospective observational study. The study settings
are two medical Pediatric Intensive Care Units (PICUs) atTable 1 Characteristics of the studied group and comparison betw
diagnosis, length of stay (LOS) and Pediatric Index of Mortality 2 (
Overall Survivors
N % N
Outcome 317 100 290
Sex
Male 160 50.5 149
Female 157 49.5 141
Diagnosis
Respiratory 152 47.9 143
CVS 57 18.0 52
CNS 44 13.9 34
Sepsis 24 7.6 21
Metabolic 29 9.1 29
Miscellaneous 11 3.5 11
Median (IQR) Median (IQR)
Age (months) 14 (6–30) 13.5 (7.0–30.0)
Weight (kg) 8 (6–12) 8.2 (6.0–12.0)
LOS (days) 6 (3–10) 6.0 (3.0–10.0)
Mean ± SD Mean ± SD
PIM2 score 5.72 ± 15.89 2.39 ± 5.49 41.38 ± 36.06
* P 6 0.05 is statistically signiﬁcant.the Pediatric Hospital (Abu El-reesh), a tertiary care pediatric
hospital afﬁliated to the Kasr Al-Ainy school of Medicine,
Cairo University and is considered the largest free pediatric
hospital in Egypt and the Middle East. The bed complement
capacity of each of the PICUs is 20 beds and is staffed by
full-time specialized pediatricians and residents with 24 h/day
coverage. Patients are admitted to the PICU from the Emer-
gency Department directly or from the general wards. The hos-
pital includes radiology and pathology departments and
clinical pathology laboratories and the PICUs have state-of-
the-art equipment enabling the performance of a wide variety
of investigations such as facilities for blood gas analyses, por-
table radiograph and ultrasound.
Study participants and data collection
Data were prospectively collected for 317 pediatric patients
admitted to the selected units over a period of one year (from
June 2012 till June 2013). Collected data at admission included
age, sex, weight, diagnosis, LOS in the PICU, PICU survival
and items included in PIM2 scoring namely; the systolic blood
pressure, pupillary reactions to bright light, partial oxygen ten-
sion (PaO2) and FIO2 at the time of PaO2 if oxygen is given
via ETT or headbox, base excess in arterial or capillary blood,
mechanical ventilation at any time during the ﬁrst hour of
PICU admission, elective admission to ICU, whether recovery
from surgery or a procedure is the main reason for ICU admis-
sion, whether the patient is admitted following cardiac bypass,
presence of high risk diagnosis. Deﬁnitions concerning these
variables and the scoring method were according to PIM2
developers’ guidelines.7 PIM2 score was calculated using an
online PIM2 calculator10 based on the regression equation
published in the PIM-2 scoring system manual.7een survivors and non survivors by demographic characteristics,
PIM2) score.
Non-survivors OR (95% CI) P
% N %
91.5 27 8.5
51.4 11 40.7 1.53 (0.69–3.42) 0.29
48.6 16 59.3
49.3 9 33.3 0.51 (0.22–1.18) 0.112
17.9 5 18.5 1.04 (0.37–2.87) 0.93
11.7 10 37 4.42 (1.87–10.45) 0.001*
7.2 3 11.1 1.60 (0.44–5.75) 0.46
10 0 0 0.90 (0.87–0.94) 0.08







Figure 1 ROC curve analysis of Pediatric Index of Mortality 2
(PIM2) for the studied subjects.
Assessment of performance of Pediatric Index of Mortality 2 67As PIM2 is calculated from the information collected at
the time a child is admitted to the intensive care, PIM2
algorithm is calculation of PIM2 (and PIM2 risk of death%)
 PIM2 val= (0.01395 * (absolute (SBP-120)))+ (3.0791 * Pupils)+
(0.2888 * (100 * FiO2/PaO2)) + (0.1040 * (absolute Base Excess))
+ (1.3352 * MechVent) (0.9282 * Elective)  (1.0244 * Recov-
ery) + (0.7507 * Bypass) + (1.6829 * HRdiag)  (1.5770 *
LRdiag)  4.8841. The PIM2 risk of death = exp PIM2 val/
(1 + expPIM2 val). For example, if a patient at the time of
admission has a recorded systolic blood pressure of 55 mmHg,
PaO2 of 110 mmHg, FiO2 0.5, base excess 6.0 the pupils
are reactive to light. Thus PIM2 val = (0.01395 * [absolute
(55–120)) + (3.0791 * 0) + (0.2888 * (100 * 0.5/110)) + (0.104 *
|6.0|)+ (1.3352 * 1) (0.9282 * 1) (1.0244 * 1)+(0.7507 * 1)
+ (1.6829 * 1)  (1.5770 * 0)  4.8841 = 1.4059. The proba-
bility of Death = exp (1.4059)/[1 + exp (1.4059)] = 0.1969
or 19.7%.7Table 2 Hosmer–Lemeshow goodness-of-ﬁt analysis for Pediatric In
across all deciles of risk.
Deciles of risk Survivors (N= 290) Non-survivors (N=
Observed Expected Observed Ex
1 31 31.009 1 0.
2 30 30.996 2 1.
3 32 31.948 1 1.
4 31 30.954 1 1.
5 31 30.934 1 1.
6 31 30.914 1 1.
7 32 30.885 0 1.
8 30 30.790 2 1.
9 30 30.280 2 1.
10 12 11.290 16 16.
* NA= Not Applicable.Statistical analysis
Statistical analysis was performed using SPSS software version
17 (SPSS Inc., Chicago, IL, USA). Descriptive statistics was
displayed as frequencies and percentages for categorical vari-
ables. The median and interquartile range (IQR) was used to
summarize continuous variables which are not normally dis-
tributed when examined by the Kolmogorov–Smirnov test
and histogram plotting. The Chi squared test was used to com-
pare categorical variables and the Mann–Whitney U-test was
used to test signiﬁcant differences of continuous variables
among survivors and non-survivors and for PIM2 score; the
student t-test of signiﬁcance was used. To assess the overall
performance of PIM2, Nagelkerke’s R2 statistic is calculated
using logistic regression analysis. Nagelkerke’s R2 is calculated
for survival outcomes, based on the difference in 2 log likeli-
hood of a model without and a model with at least one predic-
tor11 and this predictor in the current study is the PIM2 score.
Receiver Operating Characteristic (ROC) curve analysis was
performed to analyze the discriminatory ability of PMI2
score to distinguish between survivors and non-survivors.
Acceptable discrimination is represented by a concordance
‘‘c’’ statistic, also known as an Area under the Curve (AUC)
of 0.70–0.79, and a good discrimination by an AUC of P0.80,
and excellent by an AUC P0.9.12 The Hosmer–Lemeshow
goodness-of-ﬁt analysis was performed to calibrate PIM2.
Calibration refers to the agreement between observed and
expected (predicted) outcomes. Model for which expected
and observed event rates are similar is called well calibrated
and this is across different subgroups (deciles) of ﬁtted risk val-
ues. Acceptable calibration is evidenced by a P value >0.05.13
Patients were grouped by age, sex and diagnosis in order to
assess PIM2 performance across these subgroups as well in
terms of calibration and discrimination. Standardized Mortal-
ity Ratio (SMR) (The ratio of the observed to the expected
mortality) and 95% CI were calculated for the whole group
and for subgroups of patients using the OpenEpi statistical
calculator online.14 If the upper 95% CI of the SMR is <1,
then observed mortality is regarded as being lower than the
expected.4 The outcome of interest is dichotomous, either
survival (the patient is discharged alive from the PICU) or
non-survival (the patient died during his stay in the PICU).
Statistical signiﬁcance was set at P 6 0.05.dex of Mortality (PIM2) and standardized mortality ratio (SMR)
27) Total N= 317 SMR 95% CI P
pected
991 32 1.001 0.05–4.93 0.89
004 32 1.992 0.33–6.58 0.34
052 33 0.950 0.04–4.68 1
046 32 0.956 0.04–4.71 1
066 32 0.920 0.04–4.54 1
086 32 0.896 0.04–4.42 1
115 32 NA* NA* NA*
210 32 1.653 0.27–5.46 0.46
720 32 1.163 0.194–3.84 0.76
710 28 0.957 0.56–1.522 0.89
68 M. Rene labib Youssef et al.Results
The studied group consisted of 317 children admitted to the
selected PICUs. Table 1 demonstrates that males constituted
50.5% of the subjects. The median age was 14 (6–30) months.
Non-survivors constituted 8.5% of the studied group. Most
common diagnosis was respiratory diseases followed by car-
diovascular morbidities. As regards patients admitted with
metabolic disorders, the treating physicians’ preliminary diag-
nosis was ‘‘metabolic disease for investigation’’ and these
include tyrosinemia, glycogen storage disease and biotin deﬁ-
ciency disease. It is observed as well from Table 1 that non-sur-
vivors had a higher percentage of sepsis (11.1%) compared to
survivors (7.6%), however this difference was statistically
insigniﬁcant (P= 0.46). Only CNS morbidities and a higher
PIM2 score were signiﬁcantly associated with increased risk
of non-survival.
The ROC curve for the overall studied group is illustrated
in Fig. 1. The value of the AUC was 0.796 with a 95% CI of
0.675–0.916, P< 0.001 indicating a good discriminatory abil-
ity between survivors and non-survivors.
Observed and expected mortalities across deciles of risk of
non-survival according to the Hosmer–Lemeshow test is
shown in Table 2. It revealed a good calibration for PIM2 as
the differences between observed and expected mortalities
across all deciles of mortality risk were statistically insigniﬁ-
cant. SMR for each decile of risk was calculated and revealed
that PIM2 predicted mortalities for the whole group of
patients were correct in nearly all deciles, slightly lower mortal-
ities were predicted in some deciles of risk (2, 8 and 9) while a
higher mortality was predicted by PIM2 in the 7th decile of
mortality risk, where no actual mortalities were observed.Table 3 Model ﬁt and discrimination across all patients and differ
N Nagelkerke’s R2 AUC (95% C
ALL patients 317 0.50 0.796 (0.67–0
Age
612 153 0.47 0.78 (0.60–0.9
>12–30 164 0.539 0.79 (0.62–0.9
Sex
Males 160 0.647 0.85 (0.71–1.0
Females 157 0.41 0.75 (0.58–0.9
Diagnosis
Respiratory 152 0.327 0.70 (0.48–0.9
Cardiovascular 57 0.621 0.80 (0.44–1.1
CNS 44 0.636 0.85 (0.67–1.0
Sepsis 21 0.623 0.93 (0.81–1.0
Metabolic 29 NA* NA*
Miscellaneous 11 NA* NA*
LOS
66 days 188 0.66 0.89 (0.80–0.9
>6 days 129 0.243 0.63 (0.38–0.8
Weight
68 kg 159 0.513 0.79 (0.62–0.9
>8 kg 152 0.504 0.78 (0.60–0.9
* NA= not applicable.Table 3 demonstrates that the difference between observed
and PIM2 expected mortality across risk deciles was statisti-
cally insigniﬁcant (Hosmer–Lemeshow x2 is 2.850, df = 8,
P= 0.943) indicating a good calibration of PIM2 across these
deciles. Nagelkerke’s R2 is 0.50 indicating that 50% of mortal-
ities can be predicted by PIM2 score solely. Further in-depth
analyses were performed to determine the validity of PIM2
score among subgroups of patients, by age, sex, weight, LOS
and diagnosis (Tables 3 and 4). The Hosmer–Lemeshow good-
ness of ﬁt test showed no signiﬁcant differences between
observed mortalities and PIM2 expected mortalities across
subgroups of patients, except for patients diagnosed having
metabolic disorders or those with miscellaneous morbidities
where no observed deaths were recorded in these 2 subgroups.
The ROC curve analysis showed a good discriminatory ability
of PIM2 score to distinguish between survivors and non-survi-
vors across all subgroups of patients except for those with a
hospital LOS of more than 6 days where the AUC is 0.63,
95% CI 0.38–0.89, P= 0.14, indicating poor discrimination
between survivors and non-survivors in this subgroup of
patients. This poor performance in this particular group of
patients is further illustrated in Table 4, where PIM2 predicted
only 20% of observed mortalities among those patients with a
LOS more than 6 days.
It is illustrated in Table 4 that the SMR for the patients’
case-mix is 1.92 (95% CI, 1.29–2.76) indicating that PIM2 pre-
dicted mortality (4.41%) was less than the observed one
(8.5%). PIM2 predicted 51.9% of the observed mortalities
among all patients. For survivors, PIM2 predicted 99.3% of
the observed survivals. This observation was true for PIM2
predicted mortalities among all subgroups of patients dis-
played in Table 4 but the difference between the observedent subgroups of patients.
I) P Hosmer–Lemeshow x2 df P
.92) 0.000 2.850 8 0.943
66) 0.001 9.60 8 0.294
6) 0.001 9.63 8 0.292
03) 0.001 8.35 8 0.399
2) 0.001 9.152 8 0.33
3) 0.03 9.78 8 0.281
5) 0.02 10.66 7 0.15
4) 0.01 11.95 8 0.15
6) 0.01 6.57 8 0.58
NA*
NA*
8) 0.001 8.36 8 0.39
9) 0.14 8.37 8 0.39
6) 0.000 8.707 8 0.36
7) 0.001 9.212 8 0.32
Table 4 Standardized mortality ratio (SMR) (95% CI) across all patients and different subgroups of patients.
Variables N Non-survivors Survivors SMR (O/E) (95% CI) P
Observed N (%) Expected N (%) E/O % Observed N (%) Expected N (%) E/O %
All patients 317 27 (8.5%) 14 (4.41%) 51.9 290 (91.5%) 288 (90.85%) 99.3 1.92 (1.29–2.76) 0.001*
Age (months)
612 153 14 (9.15%) 8 (3.26%) 57.1 139 (90.84%) 137 (89.54%) 98.6 1.75 (0.99–2.86) 0.05*
>12–30 164 13 (7.92%) 8 (4.87%) 61.5 151 (92.07%) 151 (92.07%) 100 1.62 (0.90–2.70) 0.09
Sex
Males 160 11 (6.87%) 8 (5%) 72.7 149 (93.12%) 149 (93.12%) 100 1.37 (0.72–2.39) 0.29
Females 157 16 (10.19%) 8 (5.09%) 50 141 (89.8%) 139 (88.53%) 98.6 2 (1.18–3.17) 0.01*
Diagnosis
Respiratory 152 9 (5.92%) 3 (1.97%) 33.3 143 (94.07%) 143 (94.07%) 100 3 (1.46–5.50) 0.004*
Cardiovascular 57 5 (8.77%) 4 (7.01%) 80 52 (91.22%) 52 (91.22%) 100 1.25 (0.45–2.77) 0.58
CNS 44 10 (22.71%) 7 (15.90%) 70 34 (77.27%) 34 (77.27%) 100 1.42 (0.72–2.54) 0.26
Sepsis 24 3 (12.5%) 2 (8.33%) 66.7 21 (87.5%) 21 (87.5%) 100 1.5 (0.38–4.08) 0.46
Metabolic 29 0 24 NA*
Miscellaneous 11 0 11 NA*
LOS
66 days 188 17 (9.04%) 12 (6.38%) 70.6 171 (90.95%) 171 (90.95%) 100 1.41 (0.85–2.22) 0.16
>6 days 129 10 (7.75%) 3 (2.32%) 20 119 (92.24%) 117 (90.69%) 98.3 3.33 (1.69–5.94) 0.001*
Weight
68 kg 159 15 (9.43%) 9 (5.66%) 60 144 (90.56%) 142 (89.3%) 98.6 1.66 (0.96–2.68) 0.063
>8 kg 152 12 (7.89%) 7 (4.60%) 58.3 140 (92.10%) 140 (92.10%) 100 1.71 (0.92–2.98) 0.080
* NA= Not Applicable.
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aged 612 months, females and those diagnosed with respira-
tory morbidities. Among patients having respiratory illnesses,
PIM2 score predicted only 33.3% of observed mortalities
and 100% of survivals (SMR= 3, 95% CI 1.46–5.5) and
among patients with LOS >6 days, PIM2 predicted only
20% of observed mortalities and 98.3% of survivals (SMR
3.33, 95% CI 1.69–5.94).Discussion
The current study investigated 317 subjects admitted to the
PICUs in a large tertiary care hospital in Egypt, aiming to
assess the performance of PIM2, in terms of discriminatory
ability and calibration. The general characteristics of the stud-
ied subjects, such as nearly equal proportions of males and
females, most common diagnosis on admission; being respira-
tory morbidities and the median LOS of the studied group in
the PICU are comparable to similar studies investigating the
validity of PIM2 in PICUs in developing countries15 except
for the median age of the subjects in the current study which
was 14 months, while in the study by Hariharan et al., 2011
the mean age of the subjects was 4.9 ± 4.4 years.15
The overall performance of PIM2 in PICU settings in this
sample of Egyptian population is good. For all patients,
PIM2 has a good calibration as there is an agreement between
the observed and PIM2 expected mortalities for the studied
population (Hosmer–Lemeshow v2 is 2.850, 8 df, P= 0.943)
and it ﬁts similarly quite well across all risk categories. This
ﬁnding is consistent with many other studies. A multicenter
prospective study in ICU settings in Italy reported a similar
good calibration of PIM2 for case-mix (Hosmer–Lemeshowv2 is 9.86; 8 df, P= 0.26) for the whole population and across
all deciles of risk.9 In Korea, a retrospective study identiﬁed
a good calibration of PIM2 among pediatric patients
admitted to intensive care (Hosmer–Lemeshow v2 = 14.986;
P= 0.308).16
The present study demonstrates as well a good discrimina-
tory ability of PIM2 to differentiate survivors from non-survi-
vors (AUC 0.796, 95% CI 0.675 to 0.916, P< 0.001). This
observation is in agreement with many studies. A prospective
study in ﬁve PICU settings in the UK documented a good dis-
crimination of PIM2 model (AUC 0.84, 95% CI 0.819 to
0.853).17 In Japan, PIM2 proved excellent discrimination in a
prospective cohort study including 2536 children admitted to
the largest PICU, where the AUC value was 0.92 (95% CI
0.89–0.96).4 In India, PIM2 discriminated well between survi-
vors and non-survivors admitted to a tertiary hospital in India
with AUC 0.843 (95% CI 0.76–0.90).18 An AUC of 0.75 or
more is usually considered clinically useful. In the current
study, an AUC of 0.79 means that a randomly selected non-
survivor would have a higher PIM2 score than a randomly
selected survivor 79% of the time; it does not mean that pre-
diction of death is correct 79% of the time.17 Across subgroups
of patients, PIM2 shows a good discriminatory ability as evi-
dent by an AUC of at least 0.70 (0.48–0.93) for the group of
patients diagnosed having respiratory illnesses, except for the
group of patients with LOS >6 days, where ROC curve anal-
ysis showed an AUC of 0.63 (95% CI 0.38–0.89), P= 0.14
was observed.
Many studies investigating the validity of PIM2 in PICU
settings report an observed mortality lower than the PIM2 pre-
dicted mortality and thus an SMR less than 1. In the study of
Hariharan et al., 2011 conducted in Barbados the observed
mortality was found to be 5.5%; lower than the PIM2
70 M. Rene labib Youssef et al.predicted mortality (6.2%), SMR is 0.89.15 A prospective
study of PIM2 performance in 3 Italian PICUs and one car-
diac intensive care unit reported an observed mortality of
4.4% and a predicted mortality of 6.4%, SMR is 0.7 (95%
CI 0.6–0.8).1 In Argentina, a prospective cohort study docu-
mented an observed mortality of 2.6% in PICU compared to
a PIM2 predicted mortality of 3.06%.19 A cohort study among
children admitted to three PICU settings in Hong Kong
revealed a PIM2 predicted mortality (14.2 deaths) compared
to 7 observed deaths, SMR is 0.49 (95% CI 0.13 to 0.86).20
In contrast to these reports, it is remarkable in the current
study that a difference exists between the observed (8.5%) and
the PIM2 predicted (4.4%) mortalities for the case-mix of
patients (SMR 1.92; 95% CI 1.29–2.76). This ﬁnding is
detected as well across subgroups of patients particularly,
those aged 612 months, females, those with respiratory mor-
bidities, and those staying in the PICU for >6 days. While
for survivors, agreements between observed and expected sur-
vivors ranged from 98% up to 100%. It may be suggested that
PIM2 model has a greater ability to correctly predict survival
rather than non-survival in this case-mix of Egyptian children.
Pearson et al., 2001 discussed this controversy and they
claimed that when observed mortalities are higher than the
predicted; either there is poor model performance or poor clin-
ical performance and that clinical interpretation concerning
this is rarely objective.17 Taking into consideration the good
calibration and discrimination of the model across risk catego-
ries displayed in Table 2, it is suggested that such differences
between observed and PIM2 predicted mortalities may be
due to confounders such as the differences in the population
under study compared to the original population in which
PIM2 was ﬁrst investigated and developed, or due to inade-
quate resources or a small number of included subjects that
may be a limitation. The SMR in the present study is 1.92
(95% CI 1.29–2.76) and commonly an SMR more than 1
may be suggestive of a poor quality of care similarly, according
to Pearson et al., 2001.17 Some researchers responded to such a
high SMR in their PICU settings upon assessing PIM2 perfor-
mance by changing the coefﬁcients of the original model to
compensate for the inadequate clinical performance, but this
is considered inappropriate by the developers of this prediction
tool.17
In accordance with the present study, similar studies, par-
ticularly in developing countries have reported results similar
to that of the current study concerning an overall observed
mortality that is higher than the PIM2 predicted mortality
with a subsequent SMR of more than one. In a study including
1823 children admitted to the PICU of the Hospital de Clinicas
de Porto Alegre, the observed mortality was 10.3%. On the
other hand, PIM2 predicted mortality was 6.5%.21 In Iran, a
prospective cohort study to validate PIM2 performance in a
tertiary hospital in Tehran, the observed mortalities among
children admitted to the PICU reached 15%, while PIM2 pre-
dicted mortality was 8.3%, SMR is 1.8 (95% CI 1.28–2.46).22
Of the limitations of the study is that it is hospital-based,
thus the observed mortality rate of 8.4% cannot be generalized
to represent children’s mortalities admitted to PICUs all over
Egypt.
It is concluded that the calibration and the discriminative
ability of PIM2 scoring system aiming to distinguish survivors
from non-survivors are satisfactory. PIM2 predicted mortality
for this case-mix of Egyptian children admitted to the PICU islower than the observed mortality and the standardized mor-
tality ratio is greater than 1. PIM2 is easily calculated and is
freely available, thus provides a good incentive for ICU set-
tings in Egypt for admission of high risk patients in the light
of the limited PICU bed complement capacity in relation to
the demands.
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